Small cap round-up: InterQuest, ValiRx, Aeorema Comms
InterQuest has warned that trading during the summer, traditionally its strongest period, has been sluggish. As a result underlying earnings before interest, tax, depreciation and amortisation (EBITDA) will be in the region of 2.2m pounds. This does not include an exceptional credit of about 0.85m pounds to its income statement from the settlement of it warranty claim against the vendors of CCL.
InterQuest has warned that trading during the summer, traditionally its strongest period, has been sluggish. As a result underlying earnings before interest, tax, depreciation and amortisation (EBITDA) will be in the region of 2.2m pounds. This does not include an exceptional credit of about 0.85m pounds to its income statement from the settlement of it warranty claim against the vendors of CCL.
Biotech firm ValiRx has announced that following a successful placing to raise £2.03m it will begin work on the first in-human clinical trials of its prostrate cancer drug VAL201. It has commissioned the manufacture of the drug and retained the services of technical personnel and other specialists to conduct the trials.
Aeorema Communications, a multi-media specialist, has announced full year results for the year ended June 30th. Revenues grew to £2.9m (2011: £2.1m) producing a pre-tax loss of £0.82m (2011: loss of £0.9m).
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
CrowdStrike IT outage: a global meltdown
Millions were affected by the CrowdStrike IT outage recently, which grounded flights and took the news off the air. Was this just a hiccup or a warning of much worse to come?
By Simon Wilson Published
-
Revolut finally bags a UK banking licence – what's next for the fintech?
Revolut has finally been granted a UK banking licence following three years of negotiations with the regulator
By Kalpana Fitzpatrick Published